• Delivered 56% revenue growth and 70% Adjusted EBITDA improvement
• Preparing to launch three new precision medicine products in 2025
• Advancing late-stage therapeutic pipeline, including Phase 3 ProstACT GLOBAL trial

Telix Pharmaceuticals delivered a strong performance in FY2024, with revenue increasing by 56% to AU$783.2 million and Adjusted EBITDA improving by 70% to AU$99.3 million. The company is investing in its late-stage pipeline, including preparing to launch three new precision medicine products (Gozellix, Pixclara, and Zircaix) in 2025, and advancing the Phase 3 ProstACT GLOBAL trial for its therapeutic candidate. Telix also continued to expand its global infrastructure, completing the acquisitions of ARTMS Inc, IsoTherapeutics Group, and RLS, which significantly expand its U.S. footprint and commercial operations. The company's precision medicine business unit saw a 55% increase in revenue, reflecting continued growth in Illuccix® sales and market share gains. Telix's therapeutics business unit also saw a significant increase in R&D investment, with 74% more spent on late-stage assets, including the ProstACT GLOBAL trial and Phase 2 brain and kidney cancer programs. The company's Telix Manufacturing Solutions segment also expanded its global production infrastructure and capabilities, with the addition of new facilities and equipment.

Telix Pharmaceuticals is not providing any high-importance, price-sensitive forward-looking financial guidance at this time.

Telix Pharmaceuticals is focused on delivering its strategy and preparing for the next phase of growth, which includes launching three new precision medicine products in 2025, advancing its late-stage therapeutic pipeline, and further expanding its global infrastructure and delivery capabilities.